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Abstract
The importance of interactions between Sox and POU transcription factors in the regulation of gene
expression is becoming increasingly apparent. Recently, many examples of the involvement of SoxPOU partnerships in transcription have been discovered, including a partnership between Sox-2 and
Oct-3. Little is known about the mechanisms by which these factors modulate transcription. To better
understand the molecular interactions involved, we mapped the location of the transactivation domain of Sox-2. This was done in the context of its interaction with Oct-3, as well as its ability to
transactivate as a fusion protein linked to the DNA-binding domain of Gal4. Both approaches
demonstrated that Sox-2 contains a transactivation domain in its C-terminal half, containing a serinerich region and the C terminus. We also determined that the viral oncoprotein E1a inhibits the ability
of the Gal4/Sox-2 fusion protein to transactivate, as well as the transcriptional activation mediated
by the combined action of Sox-2 and Oct-3. In contrast, a mutant form of E1a, unable to bind p300,
lacks both of these effects. Importantly, we determined that p300 overcomes the inhibitory effects of
E1a in both assays. Together, these findings suggest that Sox-2 mediates its effects, at least in part,
through the co-activator p300.
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Transcription factors belonging to the Sox family contain a conserved HMG1 DNA-binding
domain that exhibits sequence-specific binding. At least 24 members of the Sox family expressed in many different cells and tissues have been identified (1). Members of the Sox
family are further subdivided into subgroups based on the amount of homology outside
of the HMG domain, as well as identity within the HMG domain. Unlike most transcription factors, Sox proteins bind DNA in the minor groove. Hence, Sox factors are able to
bind DNA in close proximity to transcription factors that bind in the major groove. Indeed,
interaction and/or cooperation between Sox factors and other transcription factors has
been observed, including Sox-10 with Tst-1/Oct6/SCIP (2), Sox-11 and Sox-4 with Brn-1 (3),
and Sox-2 with Oct-3 (4). Sox and POU transcription factors, such as Sox-2 and Oct-3, are
co-expressed in many different cell types during development (1, 5, 6), as well as in embryonal carcinoma (EC) and embryonic stem cells. Examples of the involvement of SoxPOU partnerships in transcriptional regulation include transcription of the FGF-4, Osteopontin (OPN), and UTF1 genes in EC cells (4, 7, 8). Recently, the interaction between Sox-2
and Oct-3 has been linked closely to the transcription of the FGF-4 gene.
Expression of the FGF-4 gene is controlled by an essential enhancer located in the untranslated region of the third exon, 3 kilobases downstream of the transcription start site
(9–11). This distal enhancer contains three important motifs: a POU motif, which binds
several octamer-binding proteins (11–14); a HMG motif, which binds several members of
the Sox transcription factor family (3, 15, 16); and a GC box, which binds Sp1 and Sp3 (14).
The functional importance of these three binding sites for the transcription of the FGF-4
gene has been demonstrated through site-directed mutagenesis studies (11, 13).2 The factors that are functionally active at the HMG and POU motifs are Sox-2 and Oct-3, respectively (11, 15, 16). Sox-2 and Oct-3 are co-expressed with the FGF-4 gene in the preimplantation mouse embryo (1, 17, 18) and in F9 EC and embryonic stem cells (12) but are downregulated upon differentiation of these cells (19–21). Furthermore, the HMG and POU sites
are separated by only three base pairs, and inserting five base pairs between these sites
results in a loss of enhancer function (4).3 Synergism and physical interaction between Sox2 and Oct-3 at their binding sites has been demonstrated (4), indicating that the FGF-4 gene
is likely to be regulated by the concerted action of Sox-2 and Oct-3.
The UTF1 and OPN genes are also co-expressed with Sox-2 and Oct-3 in F9 EC and embryonic stem cells, are down-regulated upon differentiation, and contain an HMG motif
and a POU motif (7, 8). In the UTF1 gene, the HMG and POU motifs are located next to
one another and approximately 1.8 kilobases downstream of the transcription start site,
similar to the FGF-4 gene (7). In contrast, these motifs are separated by 48 base pairs and
are located relatively close to the transcription start site in the OPN gene (8). Both genes
are regulated by Sox-2 and Oct-3. However, the UTF1 gene is regulated by the synergistic
action of Sox-2 and Oct-3 (7), whereas Sox-2 represses the Oct-3 activation of the OPN gene
(8). The repression of the OPN gene by Sox-2 requires the C-terminal region of Sox-2. Positive regulation of the FGF-4 and UTF1 genes and negative regulation of the OPN gene by
the combination of Sox-2 and Oct-3 may be attributed to the arrangement of the HMG and
POU motifs relative to each other, as well as to other transcription factor binding sites.
These studies illustrate that the effects of Sox factors on transcription are dependent on the
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context of the gene, but little is known about the mechanisms that Sox factors use to modulate transcription.
Recently, it has been reported that the transactivation domain of several Sox family
members is located in the C-terminal half of the molecule (3, 22–24). However, it is unclear
whether more than one region of the molecule is needed for transactivation, nor is it clear
whether the domains involved are dependent on transcription factors that act in concert
with Sox proteins. Transactivation by many transcription factors requires the action of a
co-activator. In the context of the HMG and POU sites of the FGF-4 gene, Sox-2 and Oct-3
activate transcription from a distance. Therefore, co-factors are likely to be involved in
bridging these proteins to the transcriptional machinery. Interestingly, E1a has been shown
to repress the Oct-3-mediated expression of the Rex-1 gene (25), as well as the transcription
of several other genes (reviewed in Ref. 26). In many cases, overexpression of the co-factor
p300, a ubiquitous protein that can interact directly with E1a, was able to overcome E1a
inhibition (27–31), indicating a possible role for p300 as a co-activator.
To advance our understanding of the molecular mechanisms by which Sox-2 acts, several questions are addressed in this study. First, which domains of Sox-2 are necessary for
transactivation? Second, does Sox-2 on its own or in combination with Oct-3 mediate its
effects through a co-activator? Here, we show that the C-terminal half of Sox-2, including
its serine-rich domain and extreme C-terminal end, is necessary for transactivation. We
also demonstrate that E1a inhibits the ability of a Gal4/Sox-2 fusion protein to transactivate,
as well as the transcriptional activation mediated by Sox-2 and Oct-3. Importantly, we
demonstrate that the co-activator p300 can recover this inhibition by E1a. These findings
are the first to implicate p300 in the action of the Sox family of transcription factors.
Experimental Procedures
Cell Culture and Transient Transfections
HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc.) supplemented with 10% fetal bovine serum (HyClone). HeLa cells were seeded at 5 ×
105 cells per 100-mm dish unless otherwise noted for 24 h prior to transfection. Cells were
transfected by the calcium phosphate precipitation method, as described previously (11,
32), incubated with the precipitate for 14–16 h, and refed with Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum. Cells were harvested the following day. Cell
extracts were prepared, and chloramphenicol acetyltransferase (CAT) and β-galactosidase
activities were determined, as reported previously (16). The total amount of transfected
DNA was kept constant by addition of null vectors. To adjust for transfection efficiency,
all transfections were normalized with either pCH110 (SV40β-gal) (Amersham Pharmacia
Biotech) or pCMVβ-gal (CLONTECH) as indicated in the figure legends. All transfections
were performed in duplicate or triplicate with representative transfections shown. Plasmid
DNA was purified by Qiagen tip-500 columns.
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Promoter-Reporter and Sox-2 Deletion Constructs
The promoter-reporter construct pCatSO3 was constructed as follows: complimentary oligonucleotides (synthesized by the Eppley Cancer Institute Molecular Biology Core Facility) containing two sets of the Sox-2 and Oct-3 binding sites (in boldface) from the FGF-4
enhancer region and BglII sites at both ends (5′-GATCTCTTTGTTTGGATGCTAATGGC
TCTTTGTTTGGATGCTAATGGA-3′) were annealed and ligated to generate multimers.
These multimers were then ligated into a BglII site upstream of the SV40 promoter of the
pCat vector (Promega) to generate pCatSO3, which contains a total of six tandem copies of
the HMG and POU sites. pCMVSox-2 3′ deletion constructs were generated by digesting
pCMVSox-2 (16) at the NotI site 5′ of the Sox-2 insert and AccI, StyI, or AatII sites within
the 3′ end of the Sox-2 sequence. The Sox-2 fragments NotI-AccI, NotI-StyI, and NotI-AatII
were isolated and ligated into pCMVΔSox-2N/X vector (pCMVSox-2 digested at the NotI
and XhoI sites flanking the Sox-2 sequence and isolated), to generate pCMVSox-21–293,
pCMVSox-21–242, and pCMVSox-21–202, respectively. pCMVSox-21–180 (pCMVNP2) has been
described previously (16).
Sox-2 was isolated from pCMVSox-2 by digesting with NotI and XhoI and then cloned
into pCR-Script Amp SK(+) (Stratagene) to generate pCRSox-2. This construct was then
used to generate additional Sox-2 deletions. pCRSox-2Δ177–293 was generated by performing
PCR with pCRSox-2 and the 3′ primer 177L (5′-CTGCTCCTGCATCATGCTGTAGCTG-3′)
and the 5′ primer 293U (5′-CGACTGCACATGGCCCAGCTC-3′). This amplified the entire
plasmid excluding the region of Sox-2 of base pairs 537–879 (amino acids 177–293). The
PCR product was then digested with DpnI, which will digest methylated DNA destroying
the parental plasmid, ligated, and transformed into bacteria. Similarly, pCRSox-2 and either the primer pair of 3′ primer 45L (5′-CCTCTTGACGCGTTCCGGGCT-3′) and 5′ primer
116U (5′-ATCCGGAAAACCAAGACGCTCATGAAG-3′) or the primer pair of 3′ primer
207L (5′-CTGCAGGGCGCTGACGTCGTA-3′) and 5′ primer 254U (5′-GATCCCGTGGTTA
CCTCTTCCTCCCA-3′) were used in PCRs to generate pCRSox-2Δ45–116 and pCRSox-2Δ207–
254, respectively. pCRSox-2Δ45–116 excludes the region of Sox-2 of base pairs 135–348 (amino
acids 45–116) and pCRSox-2Δ207–254 excludes the region of Sox-2 of base pairs 621–762
(amino acids 207–254). In the case of the Δ45–116 and Δ207–254 constructs, an additional
three base pairs were added to the 5′ end of the 5′ primers, which, after PCR and ligation,
generated a BamHI site that was used for screening. After confirmation by sequencing, the
Sox-2 deletions were isolated following NotI-XhoI digestion and ligated into pCMVΔSox2N/X.
The 5′ end of Sox-2 was tagged with the Flag epitope as follows. A 5′ primer (5′CGCGCGGGTACCGCCACCATGGACTACAAGGACGACGATGACATGTATAACATG
ATGGAGACG-3′) containing a KpnI site, a Kozac sequence, the Flag sequence, and 24 base
pairs of the 5′ Sox-2 sequence and the 3′ primer 45L (described above) were used in a PCR
with pCMVSox-2 as template. The resulting product was digested with KpnI and HindIII
and ligated into pCMVΔSox-2K/H vector (pCMVSox-2 digested with KpnI and HindIII and
isolated), generating pCMVFlagSox-2. The same method was used to insert the Flag sequence into the pCMVSox-2 deletion constructs. Sequencing confirmed that all constructs
contained the Flag sequence in-frame with Sox-2. A GFPSox-2 expression vector was constructed by ligating a SacI-KpnI Sox-2 fragment from pCRSox-2 into the SacI-KpnI sites of
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pEGFP-C1 (CLONTECH), fusing green fluorescent protein (GFP) in-frame to the N terminus of Sox-2. Positive clones were verified by sequencing.
Other plasmids utilized included pCMVOct-3 (11); Gal4/Sox-11 C3, obtained from Michael Wegner (3); pCMVOct-1, obtained from Clinton Jones (University of Nebraska, Lincoln, NE); pCMV12S E1a and pCMV12S E1aΔ2–36 (mE1a), a mutant E1a unable to bind
p300, obtained from Joseph Nevins (33); and pCMVp300 and pCMVp300del30, a mutant
p300 unable to bind E1a, obtained from David Livingston (34).
Gal4 Constructs
Gal4/Sox-2 fusions were constructed by ligating PCR-generated Sox-2 fragments into the
EcoRI and HindIII sites of the SV40Gal4 fusion vector, pM3, obtained from Ivan Sadowski
(35). The following primers were used in PCRs to generate the Sox-2 fragments indicated:
Sox-2121–319, 121U (5′-CCGTCAATGAATTCTCATGAAGAAGGATAAGTACACG-3′)
and 319L (5′-TATTTGAAGCTTCTCACATGTGCGACAGGGG-3′); Sox-2206–319, 206U
(5′-GTCAATGAATTCTGCAGTACAACTCCATGACCAGC-3′) and 319L; Sox-2206–291,
206U and 291L (5′-TATTTGAAGCTTGGGCGCAGCGGGCT-3′); Sox-2206–260, 206U and
260L (5′-TATTTGAAGCTTGGAGGAAGAGGTAACCACGGG-3′); Sox-2291–319, 291L
(5′-GTCAATGAATTCCCAGTAGACTGCACATGGCC-3′) and 319L. All resulting constructs were sequenced and determined to be in frame with Gal4 and named as indicated
in figure 3A. These constructs were co-transfected with pG5EC obtained from Ivan Sadowski (35). pG5EC contains five Gal4 DNA-binding sites upstream of the TATA box from
the adenovirus E1b gene driving the CAT reporter gene. BglII-HindIII fragments from pM3
and Gal4/Sox-2206–319 were ligated into the BglII and HindIII sites of pCMV5 (36) to generate the plasmids CMVGal4 and CMVGal4/Sox-2206–319, respectively.
Western Blotting
HeLa cells were transfected as described above. In each case, CMVβ-gal was co-transfected
with the plasmids indicated in the figure legends and used to normalize for differences in
transfection efficiency. Whole cell extracts were prepared after transfection as follows.
Cells were washed twice with 5 ml of cold phosphate-buffered saline, harvested into 1 ml
of cold phosphate-buffered saline, and centrifuged. The cell pellets were resuspended in
lysis buffer (10 mM Tris, pH 7.4–8.0, 150 mM NaCl, 1% Triton X-100, various protease and
phosphatase inhibitors) and incubated on ice for 30 min. Following centrifugation, the supernatant was transferred to a new tube, aliquoted, and stored at –80°C. Extracts were
assayed for β-galactosidase activity, normalized, and diluted in 4× sample buffer (250 mM
Tris-HCl, pH 6.8, 8% w/v SDS, 40% glycerol, 200 mM dithiothreitol, 0.4% (w/v) bromphenol blue), heated to 95–100°C for 5 min, and loaded onto a Tris-glycine gel. Gels were subjected to electrophoresis in running buffer (25 mM Tris, 0.2 M glycine, and 0.1% SDS).
Proteins were then transferred to polyvinylidene difluoride membrane (Immobilon-P, Millipore) in transfer buffer (25 mM Tris, 0.2 M glycine, 20% methanol) and membranes were
blocked in a 3% bovine serum albumin solution. For detection of the Gal4 fusion proteins,
membranes were incubated with an anti-Gal4 DNA-binding domain (DBD) polyclonal antibody (Upstate Biotechnology, Lake Placid, New York) diluted 1:2000 in blocking buffer
+0.1% Tween-20, washed in TBS/T (Tris buffered saline, 0.1% Tween-20), and incubated
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with an alkaline phosphatase-conjugated secondary antibody (Pierce) diluted 1:10 000 in
TBS/T. For detection of the Flag fusion proteins, membranes were incubated with an antiFlag M2 monoclonal antibody (Sigma) diluted 1:2000 in TBS/T, washed in TBS/T, and incubated with an alkaline phosphatase-conjugated secondary antibody (Pierce) diluted
1:2000 in TBS/T. Proteins were detected using the enhanced chemifluorescence (ECF) kit
(Amersham Pharmacia Biotech) and scanned on a Storm phosphorimager (Molecular Dynamics). Quantitation was performed using the ImageQuant analysis software (Molecular
Dynamics). All Western blots were performed in duplicate or triplicate, with representative Western blots shown.
Results
Mapping of the Sox-2 Transactivation Domains Using the Gal4 System
The HMG and POU sites located in the enhancer of the FGF-4 gene are crucial for transcription (9, 11, 13). Furthermore, overexpression studies have shown that Oct-3 on its own
can stimulate transcription of promoter-reporter constructs containing the HMG and POU
sites of the FGF-4 enhancer (11) and that the addition of Sox-2 results in a synergistic stimulation of transcription (15). Although the transactivation domains of Oct-3 have been
mapped (37–40) and Sox-2 and Oct-3 have been shown to physically interact (4), it is unclear how these factors cooperate to stimulate transcription. Therefore, to advance our understanding of this partnership, we set out to investigate the molecular mechanisms by
which Sox-2 acts by mapping the transactivation domain of Sox-2. Previous studies
demonstrated that the N-terminal region of Sox-2 (Sox-21–180) contains the DNA-binding
domain (15, 16). These studies and others (3, 22, 23) indicate that the transactivation domain of Sox-2 is likely to be located in the C-terminal half of the protein.
To map the domains of Sox-2 transactivating activity, a series of fusion proteins containing the DBD of Gal4 and various regions of Sox-2 was constructed. Gal4 fusion proteins
have been used widely to identify transactivation domains of transcription factors. In these
studies, various Sox-2 C-terminal regions were cloned into pM3, a Gal4 DBD expression
vector (Fig. 1A). These Gal4/Sox-2 fusion constructs were cotransfected into HeLa cells
with the promoter-reporter CAT construct pG5EC, containing five copies of the Gal4 binding site. The region from just C-terminal of the HMG domain to the C-terminal end (amino
acids 121–319) exhibited maximum transactivation at the concentration indicated (fig. 1B).
However, the region from the serine-rich domain to the C-terminal end, amino acids 206–
319, also contains considerable transactivation potential (fig. 1B). Constructs containing
only the serine-rich domain (Gal4/Sox-2206–291 and Gal4/Sox-2206–260) or the last 28 amino acids of the C terminus (Gal4/Sox-2291–319) failed to transactivate, whereas constructs containing both of these domains (Gal4/Sox-2121–319 and Gal4/Sox-2206–319) were able to transactivate.
This suggests that both the serine-rich domain (amino acids 206–260) and the C-terminal
end (amino acids 260–319) are necessary for transactivation. A Gal4/Sox-11 construct
(Gal4/Sox-11 C3) (3) served as a positive control and was able to transactivate in all of the
Gal4 experiments (data not shown).
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Figure 1. Mapping of the transactivation domain of Sox-2. A, schematic representation of the
fusions between the Gal4 DBD (Gal4) driven by a SV40 promoter and various regions of
murine Sox-2 as described under “Experimental Procedures.” Subscript numbers indicate
the amino acids of Sox-2 contained in the fusion proteins. B, transfection into HeLa cells
with 2 μg of the promoter-reporter construct pG5EC alone or in combination with either
5 μg of pM3 or 1 μg of the indicated Gal4/Sox-2 plasmids. C, expression of Gal4 fusion
proteins in transfected HeLa cells. Extracts from transfected cells were subjected to Western blot analysis with an antibody to the Gal4 DBD. Fusion proteins were detected by
ECF. The predicted sizes of the Gal4/Sox-2 fusion proteins are as follows: 121–319, 38 kDa;
206–319, 28.6 kDa; 206–291, 25.5 kDa; 206–260, 22.1 kDa; 291–319, 19.3 kDa; and Gal4
(pM3), 16.2 kDa. Molecular mass markers (in kDa) are shown on the left. D, transfection
into HeLa cells with 2 μg of pG5EC alone or in combination with either 5 μg of pM3 or 1
μg of Gal4/Sox-2206–319 plus 5 μg of the Gal4/Sox-2 plasmids indicated. pCMVb-gal was
used for normalization in all transfections. A constant amount of total DNA was achieved
by adding a null SV40-expressing plasmid. Results of transfections are presented as fold
induction over the expression of pG5EC alone. pG5EC is a promoter-reporter plasmid
containing five copies of the Gal4 DNA-binding site upstream of a SV40 promoter driving
the CAT gene, and pM3 is a Gal4 DBD expression vector driven by a SV40 promoter.

Western blot analysis demonstrated that the Gal4/Sox-2 fusion proteins were expressed
(fig. 1C). Although a number of nonspecific bands were detected due to the amount of
protein loaded, it is evident that each of the Gal4/Sox-2 fusion proteins was expressed at
the predicted size (see the legend to fig. 1). The slight differences in expression levels do
not correlate with transactivation levels and therefore do not explain the failure of several
Gal4/Sox-2 fusion proteins (Gal4/Sox-2206–291, Gal4/Sox-2206–260, and Gal4/Sox-2291–319) to
transactivate (compare fig. 1B and fig. 1C). Furthermore, each of the inactive constructs, as
well as Gal4, when titrated against Gal4/Sox-2206–319 in co-transfection assays, drastically
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inhibited the transactivation observed with Gal4/Sox-2206–319 (fig. 1D and data not shown).
Together, these results argue strongly that the inactive constructs are expressed and are
able to compete for binding to the Gal4 binding sites.
Deletion Mapping of the Sox-2 Transactivation Domains
To map the transactivation domains of Sox-2 in the context of its synergistic stimulation of
transcription in conjunction with Oct-3, HeLa cells were utilized because they do not contain endogenous Sox-2 or Oct-3. In addition, a promoter-reporter construct, pCatSO3, was
designed that contains six copies of the HMG and POU motifs from the FGF-4 enhancer
upstream of a SV40 promoter driving the CAT gene (fig. 2A). In HeLa cells, pCatSO3 has
minimal activity on its own and relatively little activity when co-transfected with either a
Sox-2 or an Oct-3 expression vector (fig. 2B). In contrast, a substantial stimulation was observed when pCatSO3 was co-transfected with both Sox-2 and Oct-3 expression vectors
(fig. 2, B and C), illustrating the synergistic interaction of Sox-2 and Oct-3. Additionally, a
truncated Sox-2 protein, Sox-21–180, which retains its DNA-binding and Oct-3 interacting
domain, did not stimulate pCatSO3 on its own but did induce some stimulation in conjunction with Oct-3. However, the stimulation observed with Sox-21–180 and Oct-3 was significantly less than that observed with full-length Sox-2 (Sox-21–319) and Oct-3 (fig. 2, B and
C). This latter finding suggests that Sox-2 transactivation is dependent, at least in part, on
its C-terminal region.
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Figure 2. Expression and activation of the promoter-reporter construct pCatSO3 in HeLa cells. A,
physical map showing the construction of the pCatSO3 vector. Three copies of annealed
oligonucleotides containing two sets of the HMG and POU sites of the FGF-4 enhancer
were ligated into a BglII site upstream of the SV40 promoter driving the CAT reporter
gene as described under “Experimental Procedures.” B, cells were transfected with 5 μg
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of the parent vector pCat alone or in combination with 1 μg of the CMV-expressing plasmids indicated or with 5 μg of pCatSO3 alone or in combination with 1 μg of the CMVexpressing plasmids indicated. C, cells were transfected with 5 μg of pCatSO3 alone or in
combination with the amount of CMV-expressing plasmids indicated. pCH110 (SV40βgal) was used for normalization in all transfections. A constant amount of total DNA was
achieved by adding the null CMV vector, pCMV5. Subscript numbers indicate the amino
acids of Sox-2 contained in the construct. Results of transfections are presented as fold
induction over the expression of pCat (open bars) or pCatSO3 (solid bars) alone.

To further map the transactivation domains of Sox-2 in the context of the HMG and
POU motifs of the FGF-4 enhancer, a series of CMV expression vectors containing Sox-2 Cterminal deletions was constructed (fig. 3A). These constructs were co-transfected with
pCatSO3 into HeLa cells with or without Oct-3. None of the Sox-2 deletions were able to
transactivate on their own, but all were able to stimulate transcription in conjunction with
Oct-3 (fig. 3B). However, the stimulation observed by Oct-3 and the Sox-2 deletion mutants
was reduced significantly compared with the stimulation with Oct-3 and Sox-21–319 (fig. 3B).
In all cases, the stimulation was reduced approximately to the level of that observed with
the shortest Sox-2 construct, Sox-21–180, which indicated that deleting even a small region
from the C terminus (amino acids 293–319) results in a significant reduction in transactivation. However, because the truncated proteins have little activity on their own compared
with Sox-21–319 (fig. 3B), the transactivation domain of Sox-2 is not likely to be located in the
N-terminal region. To determine whether regions other than the extreme C terminus
(amino acids 293–319) were necessary for transactivation, Sox-2 mutants containing internal deletions of amino acids 207–254 (Sox-2Δ207–254) or 177–293 (Sox-2Δ177–293) were constructed. Transfections with Oct-3 and these Sox-2 mutants resulted in decreased
stimulation of pCatSO3 (fig. 3C). These results indicate that regions other than the extreme
C terminus are necessary for transactivation. A construct containing a deletion of the HMG
domain (Sox-2Δ45–116) results in no additional stimulation above that seen with Oct-3 alone.
This was expected because the HMG domain is necessary for binding to the HMG motif
(15, 16) and for interaction with Oct-3 (4).
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Figure 3. Deletion mapping of the Sox-2 transactivation domain. A, schematic representation
of Sox-2 and the Sox-2 deletion cDNAs. All deletions were ligated into a CMV expression
plasmid as described under “Experimental Procedures.” B, HeLa cells were transfected
with 5 μg of pCatSO3 alone or in combination with 1 μg of the CMV-expressing plasmids
indicated. C, HeLa cells were transfected with 5 μg of pCatSO3 alone or in combination
with 1 μg of the CMV-expressing plasmids indicated. pCH110 or CMVb-gal was used for
normalization. A constant amount of total DNA was achieved by adding the null CMVexpressing vector, pCMV5. Results of transfections are presented as fold induction over
the expression of pCatSO3 alone. D, expression of FlagSox-2 fusion protein and FlagSox2 deletion fusion proteins in transfected cells. Extracts from transfected HeLa cells were
subjected to Western blot analysis with an antibody to Flag. Fusion proteins were detected
by ECF. The predicted sizes of the FlagSox-2 proteins are as follows: 1–319, 37.7 kDa; 1–
293, 34.8 kDa; 1–242, 29.2 kDa; 1–202, 24.8 kDa; 1–180, 22.4 kDa; D207–254, 32.5 kDa; and
D45–116, 29.9 kDa. Molecular mass markers (in kDa) are shown on the left.

To ensure that these Sox-2 deletions were being expressed, the Flag sequence was inserted at the N terminus of Sox-21–319 and all of the Sox-2 deletion constructs. Extracts from
cells transfected with these constructs were subjected to Western blot analysis with antiFlag M2 antibody. Protein expression from the FlagSox-2 deletion constructs at the predicted sizes was observed readily (fig. 3D). Although small differences in the expression
levels from several of these constructs was observed, their protein expression levels do not
account for their activity levels. Furthermore, the Flag epitope did not alter the function of
these constructs because all of the FlagSox-2 deletion constructs were able to stimulate
transcription in conjunction with Oct-3 (data not shown) similar to that observed with the
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untagged deletion constructs (fig. 3B). Because all of the above Sox-2 deletion constructs
contain the DNA-binding (HMG) and Oct-3 interaction domain, the observed stimulation
in conjunction with Oct-3 may be due to a stabilization of Oct-3 binding (see under “Discussion”).
p300 Recovers E1a Inhibition of pCatSO3 and Stimulates the Activity of Sox-2/Oct-3
Previous results have shown that E1a inhibits the synergistic activation of the Rex-1 gene
by Rox-1 and Oct-3 (25). The Rox-1 and POU sites are adjacent to each other on the Rex-1
promoter, similar to the HMG and POU sites of the FGF-4 enhancer. Furthermore, E1a
reduces the expression of FGF-4 promoter-reporter constructs containing the HMG and
POU motifs that bind Sox-2 and Oct-3, respectively.4 Therefore, the effect of E1a on Sox2/Oct-3 activation of pCatSO3 was examined. A dose-dependent decrease of transcriptional activity was observed (fig. 4A). In contrast, a mutant form of E1a (mE1a) that lacks
amino acids 2–36 and that does not bind p300 had little effect on Sox-2/Oct-3 activation of
pCatSO3 (fig. 4A). Control transfections with pCatSO3, pCMVβ-gal, or pCMVCat demonstrated that neither E1a nor mE1a has any effect on the basal expression of pCatSO3 or on
the expression of the CMV promoter, which drives several reporter genes (data not shown,
also see fig. 5C). This suggested a role for p300 in mediating the effects of Sox-2/Oct-3. To
examine this possibility, HeLa cells were transfected with pCatSO3 and with Oct-3, Sox-2,
and p300 expression vectors with or without an E1a expression vector. We observed that
p300 was able to recover, in a dose-dependent manner, the inhibition by E1a (fig. 4B). Additionally, p300 seemed to further stimulate the transcription of pCatSO3 by Sox-2 and
Oct-3 (fig. 4B). Interestingly, a p300 construct mutant for binding to E1a (p300del30) also
was able to recover the E1a inhibition (fig. 4B). Extracts from cells transfected as above, but
with the FlagSox-2 construct, were subjected to Western blot analysis with anti-Flag M2
antibody. Neither E1a nor p300 alone or in combination affected the level of FlagSox-2
protein (fig. 4C), and the Flag epitope did not alter the function of this construct (data not
shown). These results indicate that p300 can mediate the transcriptional effects of Sox-2
and Oct-3.
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Figure 4. Effects of E1a and p300 on activation of pCatSO3 by Sox-2 and Oct-3. A, transfection
of HeLa cells with 5 μg of pCatSO3 alone or in combination with 1 μg each of the CMV
expression plasmids Sox-2 and Oct-3 plus increasing amounts of CMV plasmids expressing 12S E1a (E1a) or 12S E1aΔ2–36 (mE1a), as indicated. B, transfection of HeLa cells with
5 μg of pCatSO3 alone or in combination with 1 μg each of the CMV-expressing plasmids
Sox-2 and Oct-3 along with the amount of CMV-expressing plasmids indicated. A constant amount of total DNA was achieved by adding the null CMV vector, pCMV5. Results
are presented as fold induction over the expression of pCatSO3 alone. C, expression of
FlagSox-2 fusion protein in HeLa cells transfected with FlagSox-2 alone or in combination
with E1a, mE1a, and/or p300 CMV expression vectors. Extracts from transfected cells were
subjected to Western blot analysis with an antibody to Flag. Fusion proteins were detected
by ECF, and the resulting bands were quantitated. Expression values, relative to the expression of Sox-2 only, are shown below each lane. pCH110 or CMVb-gal was used for
normalization. mE1a is a plasmid expressing a mutant E1a unable to bind p300.

To extend these findings, we examined the effect of E1a on the ability of Gal4/Sox-2 to
transactivate and whether p300 is mediating the transcriptional effects of Sox-2. For these
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studies, a Gal4/Sox-2 fusion construct driven by the CMV promoter was utilized. We observed that E1a, but not mE1a, inhibits the transactivation of the Gal4/Sox-2206–319 construct, which contains the serine-rich domain and C-terminal end (fig. 5A). As with the
pCatSO3 construct, p300 was able to recover the E1a inhibition of Gal4/Sox-2206–319 transactivation, as well as further stimulate the transactivation of Gal4/Sox-2206–319 (fig. 5B). Furthermore, we demonstrated that E1a, mE1a, and p300 had no effect on the basal expression
of the promoter-reporter construct, pG5EC (data not shown). Importantly, E1a did not
have a significant effect on the protein levels of Gal4 or Gal4/ Sox-2206–319 driven by the CMV
promoter (fig. 5C). Therefore, a reduction in Gal4/Sox-2206–319 fusion protein levels does not
account for the substantial reduction in Sox-2 transactivation by E1a (compare fig. 5B to
fig. 5C). As an added control, the effect of E1a on the nuclear localization of Sox-2 was
examined by transfecting a GFPSox-2 expression vector alone or in combination with E1a
into HeLa cells. We determined that E1a does not affect the localization of Sox-2 into the
nucleus (fig. 6), nor does E1a affect GFP itself (data not shown). This indicates that E1a is
not inhibiting the transactivation of Sox-2 by preventing Sox-2 from localizing to the nucleus. Together, these results suggest strongly that Sox-2 transactivation is mediated by the
co-activator p300.
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Figure 5. Effects of E1a and p300 on Sox-2 transactivation. A, transfection of HeLa cells with
2 μg of pG5EC alone or in combination with 1 μg of CMVGal4 or 1 μg of CMVGal4/Sox2206–319 (G4/S2206–319) expression vectors and increasing amounts of the CMV plasmids expressing 12S E1a (E1a) or 12S E1aΔ2–36 (mE1a) as indicated. B, transfection of HeLa cells
with CMVGal4/Sox-2206–319 (G4/S2206–319) alone or in combination with 0.25 μg of CMV plasmid expressing E1a and increasing amounts of the CMV plasmid expressing p300 indicated. A constant amount of total DNA was achieved by adding the null CMV vector,
pCMV5. Results are presented as fold induction over the expression of pG5EC alone. C,
expression of Gal4 protein and G4/S2206–319 fusion protein in HeLa cells transfected with
Gal4 or G4/S2206–319 alone or in combination with CMV plasmids expressing E1a and/or
p300. Extracts from transfected cells were subjected to Western blot analysis with antiGal4 DBD antibody. Fusion proteins were detected by ECF, and the resulting bands were
quantitated. Expression values for Gal4 in the presence of E1a or p300, relative to the expression of Gal4 in the absence of E1a or p300 (*) and expression values for G4/S2206–319 in
the presence of E1a and/or p300, relative to the expression of G4/S2206–319 in the absence of
E1a or p300 (#), are shown below each lane. pCMVβ-gal was used for normalization in all
transfections. mE1a is a plasmid expressing a mutant E1a unable to bind p300.
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Figure 6. Effect of E1a on the nuclear localization of Sox-2. HeLa cells (105) were transfected
with GFPSox-2 alone or in combination with CMV12S E1a. A representative field from
each transfected plate is shown. A and B, cells transfected with 1 μg of GFPSox-2. C and
D, cells transfected with 1 μg of GFPSox-2 and 0.25 μg of CMV12S E1a. Photomicrographs
were taken under brightfield (A and C) and fluorescence (B and D).

Discussion
The Transactivation Domains of Sox-2 Include a Serine-rich Domain and the Extreme Cterminal End
The transactivation domains of several Sox factors, including Sox-11, 4, and 9, have been
identified recently (3, 22, 23). In this study, we have mapped the location of the transactivation domain of the murine Sox-2 gene product in the context of two experimental promoters, including one that responds to the synergistic action of Sox-2 and Oct-3. For each
of the Sox factors studied thus far, including Sox-2, the transactivation domain has been
mapped to the C-terminal region. This is interesting, given that there is little sequence homology between the C-terminal region of Sox-2 and the Sox factors mentioned above.
However, each of these Sox family members contains a serine-rich domain in its C-terminal
region, which is necessary for transactivation (Figs. 1B and 3, B and C; Refs. 3, 22, and 23).
Studies reported here using Gal4 fusion proteins illustrate that the Sox-2 region of amino
acids 206–319 is able to transactivate when fused to the DNA-binding domain of Gal4.
Although the region of amino acids 260–291 was not tested in these Gal4 constructs, it is
unlikely that this region by itself can transactivate based on the results with the Sox-2 deletion, Sox-2Δ207–254. This deletion construct includes amino acids 260–291 but lacks the serinerich domain and exhibits significantly reduced transactivation, demonstrating the need for
both the serine-rich domain and the C-terminal end for transactivation. Additional studies
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using C-terminal deletions of Sox-2 demonstrate that the region of amino acids 121–319 is
necessary for maximal synergistic transactivation in conjunction with Oct-3. However,
considerable transactivation potential resides in the region containing the serine-rich domain and the C-terminal end (amino acids 206–319). These results further demonstrate the
need for both the serine-rich domain and C-terminal end for transactivation.
The necessity of the last 28 amino acids for Sox-2 transactivation was surprising when
compared with the results of experiments with fusion proteins of the Gal4 DBD and the
chicken homolog of Sox-2, cSox-2. Sox-2 and cSox-2 are 93% identical within the last 28
amino acids. However, our Gal4/Sox-2 construct containing a deletion of the last 28 amino
acids (Gal4/Sox-2206–291) was unable to transactivate, whereas a Gal4/cSox-2 construct containing a deletion of the last 35 amino acids was reported to transactivate (24). This may be
attributed to differences in the cell types utilized or to evolutionary differences between
murine and chicken Sox-2.
Although there was a pronounced reduction in stimulation of transcription when the
transactivation domain of Sox-2 was deleted, some synergistic transcriptional stimulation
with Oct-3 and the truncated Sox-2 proteins was observed. Given that the DNA-binding
domains of Sox-2 and Oct-3 have been shown to bind cooperatively with one another in
vitro (4), it is likely that Sox-2 lacking the C-terminal transactivation domain can bind to
the HMG motif and interact with Oct-3 to stabilize its binding to the neighboring POU
motif. In this regard, stabilization of DNA binding by transcription factors has been observed for several other homeodomain proteins (41–44). Thus, cooperative binding of Sox2 and Oct-3 to DNA may be partly responsible for the synergistic stimulation of transcription by these two transcription factors.
p300 Is a Candidate Co-activator for Sox-2 regulated Transcription
E1a is a viral protein known to influence the expression of many genes. E1a-like activity
has been found in several cell types, but the endogenous protein(s) involved has yet to be
identified. E1a has been shown to interact with several cellular proteins, including p300
and Rb, and to activate or repress the transcription of several genes (reviewed in ref. 26).
For example, E1a inhibits Rex-1 promoter-reporter gene constructs in EC cells (25). The
Rex-1 promoter contains two positive regulatory elements, a POU motif and a novel motif,
necessary for Rex-1 gene transcription in EC cells. Positive regulation of the Rex-1 promoter
requires binding of Oct-3 to the POU motif and binding of a protein designated Rox-1 to
the novel (Rox) motif (25). Because the Rox and POU motifs are juxtaposed in a manner
virtually identical to the HMG and POU motifs in the FGF-4 enhancer and because in EC
cells E1a reduces the expression of a FGF-4 promoter-reporter construct containing the
HMG and POU motifs,4 we initially examined whether E1a could affect the stimulation of
transcription mediated by Sox-2 and Oct-3. When expression vectors for E1a, Sox-2, and
Oct-3 were co-transfected with the promoter-reporter gene construct pCatSO3, containing
the HMG and POU sites, a dose-dependent inhibition of transcription was induced by E1a,
even at extremely low concentrations of the E1a expression vector. These results suggest
that E1a is inhibiting transcription either by directly interacting with Sox-2 and/or Oct-3 or
by sequestering a co-activator that interacts with Sox-2 and/or Oct-3. It has been previously
shown that E1a interacts directly with p300 (45, 46), and we determined here that a mutant
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form of E1a that cannot bind p300 (mE1a) does not inhibit expression of pCatSO3 by Sox2 and Oct-3. Therefore, our findings argue strongly that the effects of E1a are unlikely to
be due to a direct interaction between E1a and Sox-2 and/or Oct-3. Instead, E1a is likely to
be interacting with a co-activator of Sox-2 and/or Oct-3 to inhibit transcription.
Because mE1a does not inhibit Sox-2/Oct-3 stimulation of transcription, we examined a
possible role for p300 in mediating the effects of Sox-2/Oct-3. p300 is a large nuclear protein
found in most mammalian cells. It interacts with many different transcription factors (reviewed in ref. 47) and with the basal transcriptional machinery (48). However, p300 does
not appear to bind directly to DNA. Therefore, p300 is thought to elicit its effects on transcription by acting as a bridging factor between the DNA-binding transcription factors and
the basal transcriptional machinery. Overexpression of p300 has been shown to overcome
the inhibitory effects of E1a on the prolactin, p53, β-myosin heavy chain, HER-2/neu, and collagenase promoters (27–31), suggesting that p300 plays a role in the transcription of these
genes. Similarly, the work reported in this study argues that p300 is involved in the stimulation of transcription brought about by Sox-2/Oct-3. First, overexpression of p300 recovers the E1a inhibition of pCatSO3 transcription induced by Sox-2 and Oct-3. Second, in the
absence of E1a, overexpression of p300 seemed to further stimulate the transcriptional synergism of Sox-2 and Oct-3. Third, and importantly, a p300 mutant (p300del30), which is
unable to bind E1a, was also able to overcome the E1a inhibition of Sox-2/Oct-3 transcriptional activation. This last result argues that p300 is not sequestering E1a and preventing
E1a from interacting with and inhibiting another co-factor required for Sox-2/Oct-3 activation. Instead, this result argues that E1a interacts directly with p300 and prevents p300
from stimulating transcription through Sox-2/Oct-3.
We also examined whether E1a affects the ability of Gal4/Sox-2 to transactivate. As observed with Sox-2/Oct-3 activation of pCatSO3, E1a, but not mE1a, inhibited Gal4/Sox-2206–319
activation of the promoter-reporter construct pG5EC. Furthermore, p300 was able to rescue the E1a inhibition of Gal4/Sox-2206–319 activation and further stimulate the transactivation of Gal4/Sox-2206–319. Together, these studies provide strong evidence that p300 may be
a co-activator of Sox-2/Oct-3 synergistic activation through the transactivation domain of
Sox-2. In conclusion, the studies reported here describe several important findings. First,
two different experimental promoters were used to map the location of the transactivation
domain of Sox-2. Second, we determined that the co-activator p300 can mediate the effects
of Sox-2. To our knowledge, this is the first report of a co-activator that mediates the action
of a member of the Sox family of transcription factors, a family composed of at least 24
members. These findings raise several important questions that warrant further study,
namely, does p300 directly interact with Sox-2? can p300 also mediate the effects of Oct-3?
and does p300 mediate the effects of other members of the Sox family of transcription factors?
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